Literature DB >> 1613002

Morphology and classification of myelodysplastic syndromes.

P A Kouides1, J M Bennett.   

Abstract

The FAB classification has provided a common language for clinicians and pathologists in the investigation of myelodysplasia. It has also provided prognostic information, given the excellent correlation between FAB subgroup and survival (see Table 2). Refinements in immunologic and cytogenetic typing should provide further prognostic power and correlation with the underlying biologic processes.

Entities:  

Mesh:

Year:  1992        PMID: 1613002

Source DB:  PubMed          Journal:  Hematol Oncol Clin North Am        ISSN: 0889-8588            Impact factor:   3.722


  4 in total

1.  Normal platelet counts mask abnormal thrombopoiesis in patients with chronic myeloid leukemia.

Authors:  Kaili Yan; Bangsheng Ding; Jianyao Huang; Yuanyuan Dai; Shudao Xiong; Zhimin Zhai
Journal:  Oncol Lett       Date:  2015-07-17       Impact factor: 2.967

2.  Human deep tissue infection with an entomopathogenic Beauveria species.

Authors:  Markus Oliver Henke; G Sybren De Hoog; Uwe Gross; Gisbert Zimmermann; Doris Kraemer; Michael Weig
Journal:  J Clin Microbiol       Date:  2002-07       Impact factor: 5.948

3.  Phase 1-2a multicenter dose-escalation study of ezatiostat hydrochloride liposomes for injection (Telintra, TLK199), a novel glutathione analog prodrug in patients with myelodysplastic syndrome.

Authors:  Azra Raza; Naomi Galili; Natalie Callander; Leonel Ochoa; Lawrence Piro; Peter Emanuel; Stephanie Williams; Howard Burris; Stefan Faderl; Zeev Estrov; Peter Curtin; Richard A Larson; James G Keck; Marsha Jones; Lisa Meng; Gail L Brown
Journal:  J Hematol Oncol       Date:  2009-05-13       Impact factor: 17.388

4.  A case of relapsing polychondritis associated with myelodysplastic syndrome with erythroid hypoplasia/aplasia.

Authors:  Seong-Wook Heo; Kyu-Hyun Cho; Jung-Il Ryu; Seung-Hie Chung; Chae-Gi Kim; Sang-Gyung Kim; Jung-Yoon Choe
Journal:  Korean J Intern Med       Date:  2003-12       Impact factor: 2.884

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.